An in-depth look at J&J’s QuickFire Challenge program and how some of the winners have benefitted (and grown) beyond the cash grants.
Can a culture with supporting systems that are simple, efficient, and effective significantly shorten drug development times? Why not?
A look at a unique UK-based public-private partnership (P3), called Open Targets that was created to help companies choose better drug targets and reduce attrition of candidate drugs.
With the FDA’s approval of three new gene therapies, researchers and manufacturers must now figure out how streamline the development process.
GSK is looking to create a more efficient drug development system by integrating AI into its process.
As the cost of developing new medicines continues to rise, more pharmaceutical companies are looking at how artificial intelligence (AI) can help in drug development. But there are some hurdles to overcome before its full potential is reached.
Ask life sciences industry leaders and experts about blockchain and you will hear it called everything from “a game changer” to “a major disrupter.” According to the hype, the technology behind cryptocurrencies, like bitcoin, is going to completely transform day-to-day operations for life sciences companies.
“You don’t have time to invest in basic research and wait 10 years. You have to go find individuals and companies doing exciting research, engage them, and progress those new technologies through collaborations and funding,” explains Takeda’s Vincent Ling.
Automation’s advances and widespread integration into the scientific workflow can reduce drug R&D time from the usual 15 years to five, according to a study released by Frost & Sullivan. “Robotics already is meeting most relevant needs in drug discovery. Its impact in the coming few years will be remarkable,” says Cecilia Van Cauwenberghe, associate fellow and industry analyst, TechVision at Frost & Sullivan. “Robotics will make pharmaceutical processes significantly more costand time-effective and allow precise, real-time documentation of every task. That, in turn, contributes to process optimization.”
The number of precompetitive collaborations among pharmaceutical companies increased nine-fold between 2005 and 2014 when compared against the 1995 to 2005 period. Meanwhile, traditional partnerships merely doubled, according to “Partnering for Progress: How Collaborations are Fueling Biomedical Advances,” a new study by Deloitte and PhRMA.